|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACLY |
Gene summary for ACLY |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACLY | Gene ID | 47 |
| Gene name | ATP citrate lyase | |
| Gene Alias | ACL | |
| Cytomap | 17q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | A0A024R1T9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 47 | ACLY | LZE2T | Human | Esophagus | ESCC | 5.40e-05 | 4.67e-01 | 0.082 |
| 47 | ACLY | LZE4T | Human | Esophagus | ESCC | 4.34e-06 | 2.76e-01 | 0.0811 |
| 47 | ACLY | LZE5T | Human | Esophagus | ESCC | 2.62e-02 | 9.73e-02 | 0.0514 |
| 47 | ACLY | LZE7T | Human | Esophagus | ESCC | 2.41e-07 | 5.77e-01 | 0.0667 |
| 47 | ACLY | LZE8T | Human | Esophagus | ESCC | 2.02e-08 | 1.16e-01 | 0.067 |
| 47 | ACLY | LZE20T | Human | Esophagus | ESCC | 2.62e-02 | 2.39e-02 | 0.0662 |
| 47 | ACLY | LZE24T | Human | Esophagus | ESCC | 7.83e-15 | 4.71e-01 | 0.0596 |
| 47 | ACLY | LZE21T | Human | Esophagus | ESCC | 1.19e-05 | 3.33e-01 | 0.0655 |
| 47 | ACLY | LZE6T | Human | Esophagus | ESCC | 2.94e-02 | 2.16e-01 | 0.0845 |
| 47 | ACLY | P1T-E | Human | Esophagus | ESCC | 8.34e-12 | 3.20e-01 | 0.0875 |
| 47 | ACLY | P2T-E | Human | Esophagus | ESCC | 4.39e-20 | 1.94e-01 | 0.1177 |
| 47 | ACLY | P4T-E | Human | Esophagus | ESCC | 9.28e-16 | 4.33e-01 | 0.1323 |
| 47 | ACLY | P5T-E | Human | Esophagus | ESCC | 1.89e-20 | 5.12e-01 | 0.1327 |
| 47 | ACLY | P8T-E | Human | Esophagus | ESCC | 8.36e-27 | 2.94e-01 | 0.0889 |
| 47 | ACLY | P9T-E | Human | Esophagus | ESCC | 6.92e-10 | 1.76e-01 | 0.1131 |
| 47 | ACLY | P10T-E | Human | Esophagus | ESCC | 3.31e-17 | 2.25e-01 | 0.116 |
| 47 | ACLY | P11T-E | Human | Esophagus | ESCC | 1.75e-13 | 6.10e-01 | 0.1426 |
| 47 | ACLY | P12T-E | Human | Esophagus | ESCC | 4.54e-22 | 3.82e-01 | 0.1122 |
| 47 | ACLY | P15T-E | Human | Esophagus | ESCC | 2.63e-20 | 5.30e-01 | 0.1149 |
| 47 | ACLY | P16T-E | Human | Esophagus | ESCC | 9.66e-10 | 2.69e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
| GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
| GO:19026522 | Liver | HCC | secondary alcohol metabolic process | 100/7958 | 147/18723 | 3.26e-10 | 1.09e-08 | 100 |
| GO:00082032 | Liver | HCC | cholesterol metabolic process | 94/7958 | 137/18723 | 5.39e-10 | 1.72e-08 | 94 |
| GO:00338652 | Liver | HCC | nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00338752 | Liver | HCC | ribonucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00340322 | Liver | HCC | purine nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
| GO:00161252 | Liver | HCC | sterol metabolic process | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:00436482 | Liver | HCC | dicarboxylic acid metabolic process | 68/7958 | 96/18723 | 1.73e-08 | 4.14e-07 | 68 |
| GO:00066372 | Liver | HCC | acyl-CoA metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
| GO:00353832 | Liver | HCC | thioester metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
| GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
| GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
| GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
| GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
| GO:004639012 | Liver | HCC | ribose phosphate biosynthetic process | 116/7958 | 190/18723 | 1.79e-07 | 3.29e-06 | 116 |
| GO:000926012 | Liver | HCC | ribonucleotide biosynthetic process | 111/7958 | 182/18723 | 3.53e-07 | 6.03e-06 | 111 |
| GO:00066951 | Liver | HCC | cholesterol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
| GO:19026531 | Liver | HCC | secondary alcohol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
| hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
| hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
| hsa0002031 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACLY | SNV | Missense_Mutation | c.2996C>T | p.Pro999Leu | p.P999L | P53396 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-A2-A0SU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ACLY | SNV | Missense_Mutation | c.2543G>A | p.Arg848Gln | p.R848Q | P53396 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD | |
| ACLY | SNV | Missense_Mutation | novel | c.1285N>A | p.Pro429Thr | p.P429T | P53396 | protein_coding | tolerated(0.12) | benign(0.399) | TCGA-A7-A4SB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | CR |
| ACLY | SNV | Missense_Mutation | novel | c.2798A>G | p.Asp933Gly | p.D933G | P53396 | protein_coding | deleterious(0.04) | possibly_damaging(0.735) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACLY | SNV | Missense_Mutation | c.604N>T | p.Ile202Phe | p.I202F | P53396 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| ACLY | insertion | Frame_Shift_Ins | novel | c.1181_1182insGGCAGCGAGA | p.Gly395AlafsTer67 | p.G395Afs*67 | P53396 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ACLY | SNV | Missense_Mutation | c.22N>C | p.Glu8Gln | p.E8Q | P53396 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACLY | SNV | Missense_Mutation | novel | c.940C>A | p.Gln314Lys | p.Q314K | P53396 | protein_coding | tolerated(0.85) | benign(0.007) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ACLY | SNV | Missense_Mutation | rs782078720 | c.1384N>A | p.Asp462Asn | p.D462N | P53396 | protein_coding | tolerated(0.52) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| ACLY | SNV | Missense_Mutation | rs387907386 | c.1484N>A | p.Arg495His | p.R495H | P53396 | protein_coding | tolerated(0.07) | benign(0.3) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 47 | ACLY | ENZYME, DRUGGABLE GENOME | ETC-1002 | BEMPEDOIC ACID | ||
| 47 | ACLY | ENZYME, DRUGGABLE GENOME | GLUCAGON | GLUCAGON | 489538 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |